Chung, Kaman http://orcid.org/0000-0002-9586-0366
Jacobs, Colin
Scholten, Ernst T.
Mets, Onno M.
Dekker, Irma
Prokop, Mathias
van Ginneken, Bram
Schaefer-Prokop, Cornelia M.
Funding for this research was provided by:
KWF Kankerbestrijding (KUN 2013−6110)
Article History
Received: 28 September 2016
Revised: 21 March 2017
Accepted: 4 April 2017
First Online: 24 April 2017
Compliance with ethical standards
:
: The scientific guarantor of this publication is Cornelia Schaefer-Prokop.
: The authors of this manuscript declare relationships with the following companies: Dr. Jacobs reports grants from MeVis Medical Solutions AG, Bremen, Germany, outside the submitted work.Dr. Prokop reports personal fees from Bracco, personal fees from Bayer, personal fees from Toshiba, grants from Toshiba, outside the submitted work.Dr. van Ginneken reports grants from MeVis Medical Solutions, grants from Delft Imaging Systems, other from Thirona, outside the submitted work.The other authors of this manuscript (Ms. Chung, Ms. Dekker, Dr. Mets, Dr. Scholten and Prof. Schaefer-Prokop) declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: This research is funded by a grant from the Dutch Cancer Society (project no. KUN 2013–6110).
: No complex statistical methods were necessary for this paper.
: Only if the study is on human subjects:Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in Pinksy et al., Annals of Internal Medicine, 2015.
: • retrospective• diagnostic or prognostic study• performed at one institution